drugset / Trial / NCT00985504
A Study of Patients With Major Depressive Disorder and Residual Apathy
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to provide a comparison of the apathy, depression, and functional outcomes associated with switching to duloxetine or escitalopram in patients who have previously responded to treatment with a selective serotonin reuptake inhibitor (SSRI) for major depressive disorder and who have residual apathy in the absence of depressed mood.
Timeline
- Start
- 2009-09
- Primary completion
- 2010-12
- Completion
- 2010-12
Outcome
Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)
registry analysis (superiority or other test); Duloxetine vs Escitalopram; p = 0.612; Mean Difference (Final Values) -0.38 (95% CI -1.87 to 1.10); Mixed Models Analysis NCT00985504 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duloxetine | Small molecule | 60 mg | Oral |
| Subject | Duloxetine | Small molecule | 120 mg | Oral |
| Comparator | Escitalopram | Small molecule | 10 mg | Oral |
| Comparator | Escitalopram | Small molecule | 20 mg | Oral |